In terms of combination therapy, SLC1A5 was found to be overexpressed in colorectal cancer samples from patients who had developed resistance to cetuximab, an epidermal growth factor receptor inhibitor, and inhibition of SLC1A5 restored cetuximab efficacy [24]. The gene discussed is SLC1A5; the disease is colorectal cancer.